Richard L. Edelson, MD

Lerner Professor and Chairman, Dermatology
Director, Yale Comprehensive Cancer Center

Curriculum Vitae

Transimmunization Therapy

Cancer Treatment using Photopheresis graduates to a whole new level.

Research Interests

Cutaneous T cell lymphoma (CTCL), human T cell physiology, immunobiology of normal and diseased skin. Under the leadership of Dr. Edelson CTCL cells have been characterized and new and effective therapies developed. CTCL was found to be a cancer of "cutaneous T cells," which migrate to and infiltrate the skin. Dr. Edelson and his colleagues have developed an immunotherapy known as "Photopheresis," which is FDA approved and used to treat CTCL and other T cell mediated diseases in more than 100 centers worldwide.

Education:	BS, Hamilton College, 1966 MD, Yale School of Medicine, 1970
Training:	Internship: University of Chicago Residency: Massachusetts General Hospital Senior Residency: Columbia Presbyterian Hospital

Contact

Academic Office
Yale School of Medicine
333 Cedar Street. LCI 501
New Haven, CT 06520-8059
(203) 785-4091

Practice Office
Yale Dermatology Associates, P.C.
2 Church Street So, Ste 305
New Haven, CT 06519
(203) 789-1249

E-mail
redelson@yale.edu